VINCRISTINE GLS 1

VINCRISTINE GLS 1

Description

Vincristine was first isolated in 1961.It is on the World Health Organization's List of Essential Medicines.It is a vinca alkaloid that can be obtained from the Madagascar periwinkle Catharanthus roseus. The natural extraction of vincristine from Catharanthus roseus is produced at a percent yield of less than 0.0003%. For this reason, alternate methods to produce synthetic vincristine are being used

Indications:

Vincristine sulphate is used either alone or in conjunction with other oncolytic drugs for the treatment of:

• Leukaemias, including acute lymphocytic leukaemia, chronic lymphocytic leukaemia, acute myelogenous leukaemia and blastic crisis of chronic myelogenous leukaemia.
• Malignant lymphomas, including Hodgkin's disease and non-Hodgkin's lymphomas.
• Multiple myeloma.
• Solid tumours, including breast carcinoma, small cell bronchogenic carcinoma, head and neck carcinoma and soft tissue sarcomas.
• Paediatric solid tumours, including Ewing's sarcoma, embryonal rhabdomyosarcoma, neuroblastoma, Wilms' tumour, retinoblastoma and medulloblastoma.
• Idiopathic thrombocytopenic purpura. Patients with true ITP refractory to splenectomy and short-term treatment with adrenocortical steroids may respond to vincristine but the medicinal product is not recommended as primary treatment of this disorder. Recommended weekly doses of vincristine given for 3 to 4 weeks have produced permanent remissions in some patients. If patients fail to respond after 3 to 6 doses, it is unlikely that there will be any beneficial results with additional doses

Enquire Now